Benzinga | Nov 9, 2021 11:26AM EST

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $30

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $36 to $30.